2023 tables: Institutions - biological sciences - corporate

The 2023 tables are based on Nature Index data from 1 January 2022 to 31 December 2022.

Table criteria

# Institution Share 2021 Share 2022 Count 2022 Change in Adjusted Share* 2021–2022
1 F. Hoffmann-La Roche AG, Switzerland 35.34 38.72 112 19.2%
2 Alphabet Inc., United States of America (USA) 13.28 18.53 43 51.7%
3 Novartis International AG, Switzerland 17.88 17.13 79 4.2%
4 AstraZeneca plc, United Kingdom (UK) 15.52 16.21 65 13.6%
5 BGI, China 8.83 12.78 49 57.3%
6 Merck & Co., Inc., United States of America (USA) 7.39 11.47 31 68.7%
7 Pfizer Inc., United States of America (USA) 14.58 8.76 42 -34.7%
8 Regeneron Pharmaceuticals, Inc., United States of America (USA) 9.51 8.38 34 -4.1%
9 Amgen Inc., United States of America (USA) 9.40 7.19 51 -16.8%
10 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 5.80 6.92 33 29.7%
11 Moderna, Inc., United States of America (USA) 4.60 6.32 17 49.4%
12 Formosa Plastics Group, Taiwan 4.25 6.12 22 56.4%
13 Eli Lilly and Company, United States of America (USA) 3.60 5.71 23 72.4%
14 Sanofi, France 5.33 5.57 15 13.6%
15 23andMe, Inc., United States of America (USA) 8.25 5.41 11 -28.7%
16 Leidos Holdings, Inc., United States of America (USA) 5.84 4.72 70 -12.1%
17 Johnson & Johnson, United States of America (USA) 6.40 4.69 27 -20.3%
18 Vir Biotechnology, Inc., United States of America (USA) 6.10 3.87 16 -31.0%
19 Nestlé S.A., Switzerland 1.17 3.69 8 243.0%
20 Microsoft Corporation, United States of America (USA) 4.00 3.62 17 -1.4%
21 NanoString Technologies, Inc., United States of America (USA) 1.44 3.47 9 162.4%
22 Bristol-Myers Squibb (BMS), United States of America (USA) 5.28 3.20 17 -34.1%
23 New England Biolabs, Inc. (NEB), United States of America (USA) 5.53 3.11 9 -38.8%
24 Genomics England Ltd., United Kingdom (UK) 0.13 3.06 11 2410.6%
25 IBM Corporation, United States of America (USA) 2.12 2.85 20 46.1%
26 C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim), Germany 3.64 2.64 12 -21.3%
27 Gilead Sciences, Inc., United States of America (USA) 4.43 2.53 11 -37.8%
28 Novo Nordisk A/S, Denmark 3.02 2.48 29 -10.9%
29 Thermo Fisher Scientific Inc., United States of America (USA) 2.10 2.45 21 26.6%
30 Techint Group, Italy 3.79 2.35 21 -32.6%
31 Bayer AG, Germany 2.84 2.24 23 -14.3%
32 Foundation Medicine, Inc., United States of America (USA) 0.46 2.20 12 419.1%
33 Takeda Pharmaceutical Company Limited, Japan 6.12 2.09 9 -62.8%
34 BioNTech AG, Germany 3.07 2.01 6 -28.9%
35 Denali Therapeutics Inc., United States of America (USA) 1.19 1.90 3 73.8%
36 Alnylam Pharmaceuticals, Inc., United States of America (USA) 0.38 1.88 2 437.2%
37 Biogen Inc., United States of America (USA) 4.26 1.86 16 -52.7%
38 Nippon Telegraph and Telephone Corporation (NTT), Japan 0.04 1.83 6 5463.1%
39 Meta Platforms, Inc., United States of America (USA) 1.25 1.78 8 55.2%
40 Innovent Biologics, Inc., China 1.13 1.76 5 70.4%
41 BioMarin Pharmaceutical, Inc., United States of America (USA) 1.02 1.76 5 87.0%
42 Gritstone Oncology, Inc., United States of America (USA) 1.66 2 N/A
43 Bioqual, Inc., United States of America (USA) 2.49 1.60 13 -30.3%
44 Institute of Environmental Science and Research (ESR), New Zealand 0.71 1.57 6 139.2%
45 Repertoire Immune Medicines, United States of America (USA) 0.15 1.55 2 1048.4%
46 ToolGen, Inc., South Korea 1.54 3 N/A
47 China State Shipbuilding Corporation Limited (CSSC), China 1.84 1.53 45 -9.8%
48 Illumina, Inc., United States of America (USA) 1.13 1.52 14 46.5%
49 Tempus Labs, Inc., United States of America (USA) 0.41 1.45 4 280.6%
50 China National Chemical Corporation (ChemChina), China 0.77 1.44 5 102.9%

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals through 2022, in 2023 64 health-science journals were added to the Index. The 146 journals in the Nature Index were selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at nature.com/nature-index/.
  5. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2022 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.